Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
OCUL Stock Chart & Stats
$11.84
-$0.16(-1.76%)
At close: 4:00 PM EST
$11.84
-$0.16(-1.76%)
Day’s Range― - ―
52-Week Range$5.79 - $13.85
Previous CloseN/A
Volume219.73K
Average Volume (3M)3.32M
Market Cap
$2.51B
Enterprise Value$1.29B
Total Cash (Recent Filing)$391.13M
Total Debt (Recent Filing)$76.94M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 10, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding211,904,240
10 Day Avg. Volume3,537,166
30 Day Avg. Volume3,317,125
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue22.75
Enterprise Value/Gross Profit25.44
Enterprise Value/Ebitda-6.30
Forecast
1Y Price Target
$20.83Price Target Upside75.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe company recently completed an equity offering of $475 million, which combined with the existing cash balance should adequately fund both the wAMD and NPDR/DME clinical programs to completion.
Market PotentialThe company plans to target a broad label in diabetic retinopathy by including subjects with non-center-involved diabetic macular edema, potentially expanding market reach.
Regulatory ProgressThe FDA granted a Special Protocol Assessment for the planned registrational program of AXPAXLI for the treatment of non-proliferative diabetic retinopathy.
Bears Say
Clinical Trial RisksThe SOL-R patient selection criteria remove patients with residual fluid to reduce variability, increasing the chances of success.
Market CompetitionThe updates give OCUL the potential for a superiority label vs anti-VEGFs and a broad label inclusive of NPDR and DME.
Operational ChallengesThe company announced it was raising $475 million gross proceeds through a secondary offering, which will be used to fund the wAMD open-label extension study, newly announced NPDR studies, manufacturing scale-up, and precommercial activities, while maintaining a cash runway into 2028.
Ocular Therapeutix News
OCUL FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $5.79 and its highest was $13.85 in the past 12 months.
What is Ocular Therapeutix’s market cap?
Ocular Therapeutix’s market cap is $2.51B.
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Nov 10, 2025 which is in 21 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Aug 05, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.357 by -$0.033.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -0.37.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 211,904,240 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.357. Following the earnings report the stock price went down -2.834%.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Currently, no hedge funds are holding shares in OCUL
Ocular Therapeutix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.83 (75.93% Upside)
$20.83 (75.93% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 982.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $714.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.76%
12-Months-Change
Fundamentals
Return on Equity
-63.41%
Trailing 12-Months
Asset Growth
-12.72%
Trailing 12-Months
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. The company specializes in creating sustained-release drug products using its proprietary hydrogel platform technology, which allows for extended delivery of medications to the ocular surface. Ocular Therapeutix's core products include Dextenza, a drug-eluting implant for the treatment of post-surgical pain and inflammation, and OTX-TP, an investigational product for the treatment of glaucoma and ocular hypertension.
OCUL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant advancements in clinical trials and a strong financial position, indicating optimism about the future potential of AXPAXLI. The challenges mentioned, such as adjustments in rescue criteria, were addressed strategically, reflecting confidence in the drug's profile.View all OCUL earnings summariesOCUL Stock 12 Month Forecast
Average Price Target
$20.83
▲(75.93% Upside)
Technical Analysis
89bio
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
ARS Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Ownership Overview
2.51% Insiders
9.01% Mutual Funds
0.18% Other Institutional Investors
79.95% Public Companies and
Individual Investors